GlassScriptPhysician profile
Christopher R Butler
NPI 1023215803
$15,643.08
in general payments reported to CMS, 2019-2025
26 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $183 · 2021: $8,238 · 2022: $4,964 · 2023: $1,231 · 2024: $324 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $12,235.61 | 2020-2023 | Breztri, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $885.73 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Inogen, INC. | $495.95 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Regeneron Healthcare Solutions, INC. | $331.66 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $299.55 | 2020-2023 | Glassia |
| Grifols USA, LLC | $220.38 | 2022-2024 | Prolastin-C Liquid |
| Genzyme Corporation | $199.54 | 2019-2024 | |
| Pulmonx Corporation | $119.66 | 2021-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Genentech USA, INC. | $112.96 | 2019-2023 | Xolair |
| Philips North America LLC | $105.60 | 2022-2025 | Vest Therapy Und |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.97 | 2020-2025 | Jascayd, Ofev |
| Amgen INC. | $82.82 | 2022-2023 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $62.87 | 2022-2023 | Opsumit |
| United Therapeutics Corporation | $61.52 | 2021-2023 | Tyvaso |
| Resmed Corp | $54.08 | 2021-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $40.25 | 2020 | |
| Inspire Medical Systems, INC. | $37.29 | 2024-2025 | Inspire |
| Insmed, INC. | $33.91 | 2020-2025 | Brinsupri, Arikayce |
| Ethicon INC. | $31.52 | 2022 | |
| Idorsia Pharmaceuticals US INC | $28.96 | 2023 | Quviviq |
| Ucb, INC. | $24.12 | 2025 | Fintepla |
| Phadia US INC. | $18.17 | 2023 | Immunocap |
| Sunovion Pharmaceuticals INC. | $16.22 | 2019 | |
| Merck Sharp & Dohme LLC | $16.03 | 2022 | |
| Circassia INC. | $15.07 | 2020 | |
| Mylan Specialty L.P. | $13.64 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.